[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521874":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":35,"locations":44,"responsibleParty":149,"collaborators":151,"id":155,"slug":156,"hasResults":157,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":157,"sex":163,"minAge":164,"maxAge":34,"enrollmentInfo":165,"targetDuration":34,"studyType":168,"phases":169,"briefSummary":171,"conditions":172,"keywords":186,"overallStatus":47,"whyStopped":34,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":205},{"fullName":5,"class":6},"Frantz Viral Therapeutics, LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Artesunate ointment","ACTIVE_COMPARATOR","Artesunate formulated as topical ointment, 40% Four 5-day cycles of artesunate ointment every 2 weeks",[13],"Drug: Artesunate ointment",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo ointment","PLACEBO_COMPARATOR","Placebo ointment Four 5-day cycles of placebo ointment every 2 weeks",[19],"Drug: Placebo ointment",[21,29],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","topical ointment, as a non-surgical treatment",[9],[26,27,28],"Artesunic acid","Dihydroartemisinin (DHA)","Artemisinin",{"type":22,"name":15,"description":30,"armGroupLabels":31,"otherNames":32},"topical placebo ointment",[15],[33],"Placebo to artesunate ointment",null,[36,41],{"name":37,"role":38,"phone":39,"phoneExt":34,"email":40},"Mihaela Plesa","CONTACT","440-255-1155","fvtinfo@frantzgroup.com",{"name":42,"role":38,"phone":43,"phoneExt":34,"email":34},"Ahmad Bayat, MD","301-956-2523",[45,64,80,109,131],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Florida Gynecologic Oncology","RECRUITING","Fort Myers","Florida","33905","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-81.84059,26.62168,{"lat":57,"lon":56},[60],{"name":61,"role":38,"phone":62,"phoneExt":34,"email":63},"Edward C. Grendys, MD FACOG, FACS","239-334-6626","Edward.Grendys@usa.genesiscare.com",{"facility":65,"status":47,"city":66,"state":67,"zip":68,"country":51,"countryCode":52,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Ascension St. Vincent","Indianapolis","Indiana","46260",{"type":54,"coordinates":70},[71,72],-86.15804,39.76838,{"lat":72,"lon":71},[75,78],{"name":76,"role":38,"phone":34,"phoneExt":34,"email":77},"Sarah Goodrich, MD","inindgynoncresearch@ascension.org",{"name":76,"role":79,"phone":34,"phoneExt":34,"email":34},"PRINCIPAL_INVESTIGATOR",{"facility":81,"status":47,"city":82,"state":83,"zip":84,"country":51,"countryCode":52,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Cleveland Clinic Fairview Hospital","Cleveland","Ohio","44111",{"type":54,"coordinates":86},[87,88],-81.69541,41.4995,{"lat":88,"lon":87},[91,95,98,100,103,105,107],{"name":92,"role":38,"phone":93,"phoneExt":34,"email":94},"Donna White","216-445-8090","whited11@ccf.org",{"name":96,"role":38,"phone":93,"phoneExt":34,"email":97},"Megan Park","parkm2@ccf.org",{"name":99,"role":79,"phone":34,"phoneExt":34,"email":34},"Chad Michener, MD",{"name":101,"role":102,"phone":34,"phoneExt":34,"email":34},"Mariam AlHilli, MD","SUB_INVESTIGATOR",{"name":104,"role":102,"phone":34,"phoneExt":34,"email":34},"Steven Waggonner, MD",{"name":106,"role":102,"phone":34,"phoneExt":34,"email":34},"Robert DeBernardo, MD",{"name":108,"role":102,"phone":34,"phoneExt":34,"email":34},"Roberto Vargas, MD",{"facility":110,"status":47,"city":82,"state":83,"zip":111,"country":51,"countryCode":52,"cosmosGeoPoint":112,"geoPoint":114,"contacts":115},"Cleveland Clinic Foundation","44195",{"type":54,"coordinates":113},[87,88],{"lat":88,"lon":87},[116,117,118,119,121,122,123,124,125,127,129],{"name":92,"role":38,"phone":93,"phoneExt":34,"email":94},{"name":96,"role":38,"phone":93,"phoneExt":34,"email":97},{"name":99,"role":79,"phone":34,"phoneExt":34,"email":34},{"name":120,"role":102,"phone":34,"phoneExt":34,"email":34},"Lindsey Beffa, MD",{"name":104,"role":102,"phone":34,"phoneExt":34,"email":34},{"name":106,"role":102,"phone":34,"phoneExt":34,"email":34},{"name":108,"role":102,"phone":34,"phoneExt":34,"email":34},{"name":101,"role":102,"phone":34,"phoneExt":34,"email":34},{"name":126,"role":102,"phone":34,"phoneExt":34,"email":34},"Johanna Kelley, MD",{"name":128,"role":102,"phone":34,"phoneExt":34,"email":34},"Daniel Margul, MD",{"name":130,"role":102,"phone":34,"phoneExt":34,"email":34},"Michelle Kuznicki, MD",{"facility":132,"status":47,"city":133,"state":83,"zip":134,"country":51,"countryCode":52,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Hillcrest Hospital","Mayfield Heights","44124",{"type":54,"coordinates":136},[137,138],-81.4579,41.51922,{"lat":138,"lon":137},[141,142,143,144,145,146,147,148],{"name":92,"role":38,"phone":93,"phoneExt":34,"email":94},{"name":96,"role":38,"phone":93,"phoneExt":34,"email":97},{"name":99,"role":79,"phone":34,"phoneExt":34,"email":34},{"name":101,"role":102,"phone":34,"phoneExt":34,"email":34},{"name":104,"role":102,"phone":34,"phoneExt":34,"email":34},{"name":106,"role":102,"phone":34,"phoneExt":34,"email":34},{"name":108,"role":102,"phone":34,"phoneExt":34,"email":34},{"name":120,"role":102,"phone":34,"phoneExt":34,"email":34},{"type":150,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR",[152],{"name":153,"class":154},"The Cleveland Clinic","OTHER","100521874","phase-2-phase-ii-study-of-artesunate-ointment-for-the-treatment-of-vulvar-high-grade-squamous-intraepithelial-lesions-vulvar-hsil-vin23-100521874",false,"NCT06075264","Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2\u002F3)","A Phase II Double-blind, Placebo-controlled, Randomized Trial of Topical Artesunate Ointment for the Treatment of Patients With Vulvar High-grade Squamous Intraepithelial Lesions (Vulvar HSIL)","ART-VIN IIB","Inclusion Criteria:\n\n* Adult women age ≥ 18 years\n* Capable of informed consent\n* Able to collaborate with planned follow-up (transportation, compliance history, etc)\n* Biopsy diagnosis of high-grade vulvar dysplasia (VIN2, VIN3, VIN2\u002F3, HSIL), including both new and recurrent disease. A biopsy diagnosis of vulvar high-grade squamous intraepithelial lesion within the previous 3 months which was not excised or otherwise treated may be accepted for study entry.\n* Positive HPV test at study entry (any genotype).\n* Women of childbearing potential agree to use birth control during the dosing phase (through week 8).\n* Laboratory values at Screening of:\n\n  * Serum alanine transaminase (SGPT\u002FALT) \\\u003C 5 x upper limit of normal (ULN)\n  * Serum aspartate transaminase (SGOT\u002FAST) \\\u003C 5 x ULN\n  * Serum Bilirubin (total) \\\u003C 2.5 x ULN\n  * Serum Creatinine ≤ 1.5 x ULN\n* Weight ≥ 50kg\n\nExclusion Criteria:\n\n* Pregnant and nursing women\n* Concurrent anal, vulvar, or cervical cancer\n* HIV-positive participants with a CD4 count \\\u003C 200\n* Participants infected with HIV-1 if not on a stable, suppressive antiretroviral therapy (ART) regimen.\n* Unwillingness to undergo an excisional procedure at week 18 to either remove HSIL lesions, or to document histologic regression at a site where HSIL was present at study entry.\n* Currently receiving systemic chemotherapy or radiation therapy for another cancer.\n* Concomitant use of Efavirenz for HIV antiretroviral treatment\n* Concomitant use of strong UGT inhibitors\n* Concomitant use of imiquimod, cidofovir, or 5-fluorouracil (5-FU) for the duration of the study\n* Concurrent dermatological conditions affecting the vulva (e.g., herpetic lesion, Crohn's disease, hidradenitis suppurativa) or vulvar dermatoses (e.g., lichen sclerosis or planus, atopic dermatitis, genital atrophy).\n* Concurrent treatment with systemic corticosteroids","FEMALE","18 Years",{"count":166,"type":167},27,"ESTIMATED","INTERVENTIONAL",[170],"PHASE2","This is a phase II double-blind, placebo-controlled study of artesunate ointment for the treatment of HPV-associated vulvar HSIL (usual type vulvar intraepithelial neoplasia 2\u002F3).",[173,174,175,176,177,178,179,180,181,182,183,184,185],"Vulvar Diseases","HPV Infection","Vulvar HSIL","Pre-Cancerous Dysplasia","HPV Disease","VIN, Usual Type","VIN 2 of Usual Type","VIN 3 of Usual Type","Vin II","Vin III","VIN Grade 2","VIN Grade 3","High Grade Intraepithelial Neoplasia",[187,188,189,190,191,192,193,194,195],"topical treatment","ointment","non-surgical","vulvar cancer prevention","high-risk HPV","human papillomavirus","HPV","vulvar HSIL","High grade lesions","2025-08-13",{"date":198,"type":199},"2025-08-14","ACTUAL",{"date":201,"type":199},"2023-12-06",{"date":203,"type":167},"2027-12",{"name":5,"class":6},5]